Impel Pharmaceuticals Inc.
NASDAQ: IMPL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Paolillo
- Employees
- 160
- Headquarters
- Seattle, United States
- IPO year
- 2021
- Market cap
- $956.0K
- Website
- https://impelpharma.com
Loading IMPL…
Loading profile data…Frequently asked questions about IMPL
What does Impel Pharmaceuticals Inc. (IMPL) do?
Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotami...
Where does IMPL trade?
Impel Pharmaceuticals Inc. (IMPL) trades on the NASDAQ Global Market.
What sector is IMPL in?
Impel Pharmaceuticals Inc. (IMPL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Impel Pharmaceuticals Inc.?
Leonard S. Paolillo is the chief executive officer of Impel Pharmaceuticals Inc. (IMPL).
Where is Impel Pharmaceuticals Inc. headquartered?
Impel Pharmaceuticals Inc. is headquartered in United States.
Does IMPL pay a dividend?
Impel Pharmaceuticals Inc. (IMPL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMPL go public?
Impel Pharmaceuticals Inc. (IMPL) completed its initial public offering in 2021.